<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066257</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_111</org_study_id>
    <nct_id>NCT04066257</nct_id>
  </id_info>
  <brief_title>Evaluate the PK of Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers</brief_title>
  <official_title>An Open-Label, Randomized, Crossover Study to Evaluate the Pharmacokinetic Interaction After Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the pharmacokinetic interaction between tegoprazan and
      combination of metronidazole, tetracycline and bismuth in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A open-label, randomized, multiple dose, two arm, two period, crossover study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Actual">April 25, 2019</completion_date>
  <primary_completion_date type="Actual">February 22, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-12 of tegaprazan and metabolite M1</measure>
    <time_frame>pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in period1 ,2.</time_frame>
    <description>Area under the plasma concentration versus time curve of tegoprazan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of tegaprazan and metabolite M1</measure>
    <time_frame>pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in period1 ,2.</time_frame>
    <description>Peak Plasma Concentration of tegoprazan and metabolite M1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-6 of metronidazole, tetracycline and bismuth</measure>
    <time_frame>pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in period1 ,2.</time_frame>
    <description>Area under the plasma concentration versus time curve of metronidazole, tetracycline and bismuth</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of metronidazole, tetracycline and bismuth</measure>
    <time_frame>pre-dose on Day 1,5,6,7 and post-dose up to 24 hours on Day 7 in period1 ,2.</time_frame>
    <description>Peak Plasma Concentration of metronidazole, tetracycline and bismuth</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tegoprazan 50 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of Tegoprazan 50 mg twice daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tegoprazan 50 mg+MTN 500 mg+TCL 500 mg+BIS 300 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of Tegoprazan 50 mg twice daily, Metronidazole 500 mg three times daily, and Tetracycline hydrochloride 500 mg &amp; Tripotassium bismuth dicitrate 300 mg four times daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MTN 500 mg+TCL 500 mg+BIS 300 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral administration of Metronidazole 500 mg twice daily, Tetracycline hydrochloride 500 mg &amp; Tripotassium bismuth dicitrate 300 mg four times daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan</intervention_name>
    <description>Tegoprazan 50 mg tablet</description>
    <arm_group_label>Tegoprazan 50 mg</arm_group_label>
    <arm_group_label>Tegoprazan 50 mg+MTN 500 mg+TCL 500 mg+BIS 300 mg</arm_group_label>
    <other_name>K-CAB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole</intervention_name>
    <description>Metronidazole 250 mg tablet</description>
    <arm_group_label>MTN 500 mg+TCL 500 mg+BIS 300 mg</arm_group_label>
    <arm_group_label>Tegoprazan 50 mg+MTN 500 mg+TCL 500 mg+BIS 300 mg</arm_group_label>
    <other_name>Flasinyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tetracycline</intervention_name>
    <description>Tetracycline hydrochloride 250 mg capsule</description>
    <arm_group_label>MTN 500 mg+TCL 500 mg+BIS 300 mg</arm_group_label>
    <arm_group_label>Tegoprazan 50 mg+MTN 500 mg+TCL 500 mg+BIS 300 mg</arm_group_label>
    <other_name>Teracyclin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bismuth</intervention_name>
    <description>Tripotassium bismuth dicitrate 300 mg tablet</description>
    <arm_group_label>MTN 500 mg+TCL 500 mg+BIS 300 mg</arm_group_label>
    <arm_group_label>Tegoprazan 50 mg+MTN 500 mg+TCL 500 mg+BIS 300 mg</arm_group_label>
    <other_name>Denol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult aged ≥ 19 and &lt; 55 year-old on the day of obtaining the informed
             consent.

          -  Body mass index (BMI) ≥ 17.5 kg/m2 and &lt; 28.0 kg/m2 with a body weight ≥ 55 kg at
             screening.

          -  H. pylori negative.

        Exclusion Criteria:

          -  Medical History

               1. History or evidence of clinically significant disease

               2. History of gastrointestinal disease (e.g., esophageal disease such as esophageal
                  achalasia or stenosis, and Crohn's disease) or surgery that may affect the
                  absorption of a drug.

               3. History or presence of hypersensitivity to IMPs, components of IMPs,
                  benzimidazoles, imidazole derivatives or tetracycline antibiotics

          -  Laboratory tests(in blood)

             1) Total bilirubin, AST (GOT), ALT (GPT) &gt; 1.5 X upper limit of normal (ULN) at
             screening

          -  History of drug/alcohol abuse

          -  Participated in other study and received investigational product within 3 months prior
             to the first study dose.

          -  taken a medication known to substantially induce or inhibit a drug metabolizing enzyme

          -  Not able to use a medically acceptable contraceptive method throughout the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min-Gul Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk university hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 20, 2019</study_first_submitted>
  <study_first_submitted_qc>August 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>August 22, 2019</last_update_submitted>
  <last_update_submitted_qc>August 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-Drug interaction</keyword>
  <keyword>pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metronidazole</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
    <mesh_term>Bismuth</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

